SlideShare a Scribd company logo
1 of 36
JAUNDICE

Vineela Nekkanti
V Pharm.D
Contents of the topic
 Definition
 Classification
 Signs and symptoms
 Diagnosis

 Pathophysiology
 Prevention

 Treatment
Definition :
Jaundice, as in the French jaune, refers to the yellow
discoloration of the skin.

Also known as Icterus
Jaundice is a liver disease characterized by elevated
levels of bilirubin in the blood termed as
hyperbilirubinaemia.
Normal range of serum bilirubin concentration is 0.31.3mg/dl
Jaundice occurs when bilirubin levels exceeds 2mg/dl
 Introduction to Bilirubin :
Bilirubin is a orange-yellow pigment formed in the liver
by the breakdown of hemoglobin and excreted in bile.

 Two types of bilirubin :
Conjugated and Unconjugated bilirubin

 Sources of Bilirubin :
• Catabolism of heme of hemoglobin (80-85%)
• Non-hemoglobin heme containing pigments such as
myoglobin, catalase and cytochromes
Conjugated Bilirubin

Unconjugated Bilirubin

Water soluble

Water Insoluble

It reacts quickly to produce
azobilirubin

It reacts slowly to produce
azobilirubin

It produces azobilirubin only in
the presence of dye

It produces azobilirubin in the
absence of dye

Known by Direct bilirubin

Known by Indirect bilirubin
Metabolism of Bilirubin
Types of Jaundice
 Prehepatic Jaundice
 Intrahepatic jaundice
 Post hepatic Jaundice
Type of Jaundice

Pre-Hepatic

Intra-hepatic

Post-Hepatic

Other Name

Hemolytic
jaundice

Hepatocellular
Jaundice

Obstructive/
Regurgitation
Jaundice

Cause

Increased
hemolysis of
erythrocytes

Examples

Malaria, sickle cell
anemia,
incompatible
blood transfusion

Dysfunction of liver Obstruction of bile
due to damage to duct – prevents the
parenchymal cells passage of bile into
intestine
Viral
infection(hepatitis),
poisons and
toxins(chloroform,
carbon
tetrachloride,
phosphorus),
cirrhosis

Gallstones, cancer
of pancreas, gall
bladder and bile
duct
Type of
Jaundice

Pre-Hepatic

Intra-hepatic

Post-Hepatic

Biochemical
characteristics

serum
unconjugated
bilirubin

serum
conjugated and
unconjugated
bilirubin, SGPT
and SGOT

Serum
conjugated
bilirubin and ALP

Clinical
manifestations

Dark brown color
stools

Nausea and
anorexia

Nausea; GI pain
and clay colored
feces

Absent

Absent

Increased

Increased

Stercobilinogen Increased
content
Urobilinogen
content

Increased
Etiology/Causes
Common Drugs Associated With
Hyperbilirubinemia
HEPATOCELLULAR CAUSES
•
•
•
•
•
•
•
•
•
•
•

Acetominophen
Alcohol
Amiodarone
Azulfidine
Carbenicillin
Clindamycin
Colchicine
Cyclophosphamide
Diltiazem
Ketoconazole
Methyldopa

•
•
•
•
•
•
•
•
•
•

Niacin
Nifedipine
NSAIDs
Propylthiouracil
Pyridium
Pyrazinamide
Quinidine
Rifampicin
Salicylates
Verapamil
Common Drugs Associated With
Hyperbilirubinemia
CHOLESTATIC CAUSES





















Amitriptyline
Androgenic steroids (B)
Atenolol
Augmentin
Azathioprine
Bactrim (D)
Benzodiazeprines
Captopril
Carbamazole
Chlordiazepoxide (D))
Clofibrate
Coumadin
Cyclosporine
Danazol (B)
Dapsone
Disopyramide
Erythromycin
Estrogens (B)
Ethambutol
Floxuridine






















5-Flucytosine
Fluoroquinolones
Griseofulvin
Haloperidol (D)
Labetolol
Nicotinic acid
NSAIDs
Penicillins
Phenobarbital
Phenothiazines (D)
Phenytoin
Tamoxifen
Tegretol
Thiabendazole (D)
Thiazides
Thiouracil
Tolbutamide (D)
Tricyclics (D)
Verapamil
Zidovudine
Etiopathogenesis
1.
2.
3.
4.

5.

Increased bilirubin
production
Reduced bilirubin uptake
by hepatic cells
Disrupted intracellular
conjugation
Disrupted secretion of
bilirubin into bile
canaliculi
Intra/extra-hepatic bile
duct obstruction

Lead to increases in
free (unconj.) bilirubin

Result in rise in conj.
bilirubin levels
1. INCREASED BILIRUBIN PRODUCTION
(unconj. Hyperbilirubinemia)


Hemolysis


Increased destruction of RBCs
eg sickle cell anemia, thalassemia





Drastic increase in the amount of bilirubin produced
Unconj. bilirubin levels rise due to liver’s inability to catch up to the
increased rate of RBC destruction
Prolonged hemolysis may lead to precipitation of bilirubin salts in the
gall bladder and biliary network - result in formation of gallstones and
conditions such as cholecystitis and biliary obstruction



Other



Degradation of Hb originating from areas of tissue infarctions and
hematomas
Ineffective erythropoiesis
2. DECREASED HEPATIC UPTAKE
(unconj. Hyperbilirubinemia)
 Several drugs have been reported to inhibit
bilirubin uptake by the liver
e.g. novobiocin, flavopiridol
Hepatic cell

Plasma
Alb

Bile

B
B + GST

Alb

B :GST

B + UDPGA

CB
UGT1A1

sER

MRP2
3) DISRUPTED INTRACELLULAR
CONJUGATION
(unconj. Hyperbilirubinemia)

Neonatal jaundice
occurs in 50% of newborns
fetal bilirubin is eliminated by mother’s liver
causes:
hepatic mechanisms are not fully developed resulting in
decreased ability to conjugate bilirubin
rate of bilirubin production is increased due to shorter
lifespan of RBCs

Acquired disorders
hepatitis, cirrhosis
impaired liver function
Crigler-Najjar Syndrome, Type I (CN-I)

recessive allele; mutation-induced loss of
conjugating ability in the critical enzyme
glucuronosyltransferase
CN-II greatly reduced but detectable
glucuronosyltransferase activity due to mutation
(predominantly recessive); enzymatic activity can be
induced by drugs
 Gilbert’s Syndrome
glucuronosyl transferase activity reduced to 1030% of normal; also accompanied by defective
bilirubin uptake mechanism
4) DISRUPTED SECRETION OF BILIRUBIN INTO BILE
CANALICULI
(conj. Hyperbilirubinemia)


Dubin–Johnson Syndrome


mild conj. hyperbilirubinemia, but can increase with concurrent illness,
pregnancy, and use of oral contraceptives; otherwise asymptomatic






Inability of hepatocytes to secrete CB after it has formed
Due to mutation in the MRP2 gene (autosomal recessive trait)

Rotor Syndrome


Autosomal recessive condition characterized by increased total bilirubin
levels due to a rise in CB



Caused by a defect in transport of bilirubin into bile
5) Intra/extra-hepatic bile duct obstruction



Intra-hepatic
Obstruction of bile canaliculi, bile ductules or hepatic ducts

 Extra-hepatic
Obstruction of cystic duct or common bile duct
Cholecystitis

 Obstruction causes backup and reabsorption of CB which

results in increased blood levels of CB
Signs and Symptoms
 Skin and sclerae - yellow
 Stool - light colour, clay coloured
 Dark urine

 Pain in abdomen
 Itching
 Trouble with sleeping
 Fatigue
 Swelling
 Ascites
 Mental confusion
 Coma
 Bleeding
Diagnosis
 Medical history and examination

 Urine test
 Liver function and blood tests
 Imaging tests
 Liver biopsy
 Medical history and physical examination
Patient interview for
-

abdominal pain, itchy skin or weight loss
malaria or hepatitis A
change of colour in your urine and stools
history of prolonged alcohol misuse
Flu like symptoms
Medications
Occupation

Physical examination :
-

Yellowish discoloration of eye and skin
Swelling of legs, ankle and feet
Hepatomegaly
 Urine test :
- to measure levels of a substance called urobilinogen
- more than normal urobilinogen levels : Pre and Intra hepatic
jaundice
- Less than normal urobilinogen level : Post hepatic jaundice

 Liver function and blood tests :
Damage to liver releases liver enzymes like SGPT, SGOT and ALP
and proteins, this indicates
- Hepatitis

- Alcoholic liver disease
- cirrhosis
 Imaging tests
- CT Scan
- MRI Scan

- Ultrasound Scan
- Endoscopic retrograde cholangiopancreatography (ERCP)
Used to check for abnormalities inside the liver or bile duct

systems.

 Liver biopsy
Used to diagnosis Cirrhosis and liver cancer.
Jaundice treatment
The treatment given to someone with jaundice will depend on what
type they have, how serious it is and what caused it.
It may include tackling an underlying condition such as malaria
and bothersome symptoms, such as itching.
For genetic conditions that don't get better, like sickle cell anaemia,
a blood transfusion may be given to replenish red blood cells in the
body.
If the bile duct system is blocked, an operation may be needed to
unblock it. During these procedures measures may be taken to
help prevent further problems, such as removal of the gallbladder.
If the liver is found to be seriously damaged, a transplant may be
an option
Treatment & Therapeutic Considerations
PHOTOTHERAPY
 Through absorption of the wavelengths at the blue end of the spectrum

(blue, green and white light), bilirubin is converted into water-soluble
photoisomers. This transformation enhances the molecule’s excretion
into bile without conjugation.
PHENOBARBITAL
 This drug is not approved by FDA for use in neither adult nor
pediatric hyperbilirubinemia patients, due to possibility of significant
systemic side-effects.
 Exact pathway is not known, but it is believed to act as an inducing
agent on UDP-glucuronosyl transferase, thereby improving conjugation
of bilirubin and its excretion.

ALBUMIN
 A 25% infusion can be used in treating hyperbilirubinemia (esp. due to
hemolytic disease).
 It is used in conjunction with exchange transfusion to bind bilirubin,
enhancing its removal.
CLOFIBRATE (ATROMID-S)
 This drug has been shown to reduce bilirubin levels via an unknown
mechanism.
 Clofibrate is also associated with increased risk of developing
cholelithiasis, cholecystitis, as well as functional liver abnormalities,
which can worsen hyperbilirubinemia.

PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY
 Allows extraction of stones and thus removal of the source of
obstruction when present.
Prevention of Jaundice :
• Limit alcohol intake to not more than two drinks a day for
men or one drink a day for women.

• Avoid exposure to industrial chemicals.
• Do not use illegal drugs.
• Do not share needles or nasal snorting equipment.
• Vaccination : Hepatitis A and Hepatitis B
• Maintain healthy body weight.
Jaundice V PharmD by Vineela.N

More Related Content

What's hot

Drug induced blood disorders
Drug induced blood disordersDrug induced blood disorders
Drug induced blood disordersAnjumAhamadi1
 
Critical evaluation of biomedical literature - clinical pharmacy
Critical evaluation of biomedical literature - clinical pharmacyCritical evaluation of biomedical literature - clinical pharmacy
Critical evaluation of biomedical literature - clinical pharmacyShaistaSumayya
 
Drug induced hematological disorders
Drug induced hematological disordersDrug induced hematological disorders
Drug induced hematological disordersDr. Jibin Mathew
 
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...Soujanya Pharm.D
 
Pain pathways & Pain management for Pharm.D
Pain pathways & Pain management for Pharm.DPain pathways & Pain management for Pharm.D
Pain pathways & Pain management for Pharm.DSoujanya Pharm.D
 
Systematic approach in answering DI queries request
Systematic approach in answering   DI queries requestSystematic approach in answering   DI queries request
Systematic approach in answering DI queries requestKhadga Raj
 
14ab1t0026 packing and labelling of radiopharmaceuticals
14ab1t0026   packing and labelling of radiopharmaceuticals14ab1t0026   packing and labelling of radiopharmaceuticals
14ab1t0026 packing and labelling of radiopharmaceuticalsRamesh Ganpisetti
 
DRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATIONDRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATIONaishuanju
 
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)Anjali Rarichan
 
14ab1t0012 dispensing of narcotics and controlled substances
14ab1t0012   dispensing of narcotics and controlled substances14ab1t0012   dispensing of narcotics and controlled substances
14ab1t0012 dispensing of narcotics and controlled substancesRamesh Ganpisetti
 
Antidotes and its clinical application
Antidotes and its clinical applicationAntidotes and its clinical application
Antidotes and its clinical applicationkritijain857168
 
7 continuing professional development programs
7 continuing professional development programs7 continuing professional development programs
7 continuing professional development programsChanukya Vanam . Dr
 
Drugs induced hematological disorders 2020
Drugs induced hematological disorders 2020Drugs induced hematological disorders 2020
Drugs induced hematological disorders 2020Pravin Prasad
 
Epilespy pharmacotherapy
Epilespy pharmacotherapyEpilespy pharmacotherapy
Epilespy pharmacotherapysara_abudahab
 
Drug induced hematological disorder
Drug induced hematological disorderDrug induced hematological disorder
Drug induced hematological disorderChandrakant More
 

What's hot (20)

Drug Therapy Monitoring
Drug Therapy MonitoringDrug Therapy Monitoring
Drug Therapy Monitoring
 
Drug induced blood disorders
Drug induced blood disordersDrug induced blood disorders
Drug induced blood disorders
 
Pharmacotherapy of ibd
Pharmacotherapy of ibdPharmacotherapy of ibd
Pharmacotherapy of ibd
 
14ab1t0009 newsletter
14ab1t0009    newsletter14ab1t0009    newsletter
14ab1t0009 newsletter
 
Critical evaluation of biomedical literature - clinical pharmacy
Critical evaluation of biomedical literature - clinical pharmacyCritical evaluation of biomedical literature - clinical pharmacy
Critical evaluation of biomedical literature - clinical pharmacy
 
Drug induced hematological disorders
Drug induced hematological disordersDrug induced hematological disorders
Drug induced hematological disorders
 
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
Pathophysiology of Parkinsonism and its management for Pharm.D (Pharmacothera...
 
Pain pathways & Pain management for Pharm.D
Pain pathways & Pain management for Pharm.DPain pathways & Pain management for Pharm.D
Pain pathways & Pain management for Pharm.D
 
Systematic approach in answering DI queries request
Systematic approach in answering   DI queries requestSystematic approach in answering   DI queries request
Systematic approach in answering DI queries request
 
14ab1t0026 packing and labelling of radiopharmaceuticals
14ab1t0026   packing and labelling of radiopharmaceuticals14ab1t0026   packing and labelling of radiopharmaceuticals
14ab1t0026 packing and labelling of radiopharmaceuticals
 
DRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATIONDRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATION
 
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
 
14ab1t0012 dispensing of narcotics and controlled substances
14ab1t0012   dispensing of narcotics and controlled substances14ab1t0012   dispensing of narcotics and controlled substances
14ab1t0012 dispensing of narcotics and controlled substances
 
Antidotes and its clinical application
Antidotes and its clinical applicationAntidotes and its clinical application
Antidotes and its clinical application
 
Medication history Interview
Medication history InterviewMedication history Interview
Medication history Interview
 
7 continuing professional development programs
7 continuing professional development programs7 continuing professional development programs
7 continuing professional development programs
 
Drugs induced hematological disorders 2020
Drugs induced hematological disorders 2020Drugs induced hematological disorders 2020
Drugs induced hematological disorders 2020
 
Epilespy pharmacotherapy
Epilespy pharmacotherapyEpilespy pharmacotherapy
Epilespy pharmacotherapy
 
Extracorporeal removal of drugs
Extracorporeal removal of drugsExtracorporeal removal of drugs
Extracorporeal removal of drugs
 
Drug induced hematological disorder
Drug induced hematological disorderDrug induced hematological disorder
Drug induced hematological disorder
 

Similar to Jaundice V PharmD by Vineela.N (20)

JAUNDICE
JAUNDICEJAUNDICE
JAUNDICE
 
HEME DEGRADATION - JAUNDICE
HEME DEGRADATION - JAUNDICE HEME DEGRADATION - JAUNDICE
HEME DEGRADATION - JAUNDICE
 
Liver function tests 2020
Liver function tests 2020Liver function tests 2020
Liver function tests 2020
 
Liver function tests and interpretation
Liver function tests and interpretation Liver function tests and interpretation
Liver function tests and interpretation
 
Heme Catabolism.ppt
Heme Catabolism.pptHeme Catabolism.ppt
Heme Catabolism.ppt
 
Postoperative jaundice
Postoperative jaundicePostoperative jaundice
Postoperative jaundice
 
All about Jaundice
All about JaundiceAll about Jaundice
All about Jaundice
 
LIVER FUNCTIONS TESTS -1-
LIVER FUNCTIONS TESTS -1-LIVER FUNCTIONS TESTS -1-
LIVER FUNCTIONS TESTS -1-
 
Jaundice pathology
Jaundice pathologyJaundice pathology
Jaundice pathology
 
Red Blood Cell Destruction kau
Red Blood Cell Destruction kauRed Blood Cell Destruction kau
Red Blood Cell Destruction kau
 
Jaundice.pptx
Jaundice.pptxJaundice.pptx
Jaundice.pptx
 
jaundice.pptx
jaundice.pptxjaundice.pptx
jaundice.pptx
 
jaundice presentation portable display format pdf.pdf
jaundice presentation portable display format pdf.pdfjaundice presentation portable display format pdf.pdf
jaundice presentation portable display format pdf.pdf
 
Jaundice (new).ppt
Jaundice (new).pptJaundice (new).ppt
Jaundice (new).ppt
 
Jaundice
JaundiceJaundice
Jaundice
 
Bilirubin ...dotx
Bilirubin ...dotxBilirubin ...dotx
Bilirubin ...dotx
 
Jaundice
JaundiceJaundice
Jaundice
 
LIVER FUNCTION TEST
LIVER FUNCTION TESTLIVER FUNCTION TEST
LIVER FUNCTION TEST
 
Bilirubin Metabolism Presentation Yr 2 CHOs 2023 - Copy.pptx
Bilirubin Metabolism Presentation Yr 2 CHOs 2023 - Copy.pptxBilirubin Metabolism Presentation Yr 2 CHOs 2023 - Copy.pptx
Bilirubin Metabolism Presentation Yr 2 CHOs 2023 - Copy.pptx
 
jaundice 22.pptx
jaundice 22.pptxjaundice 22.pptx
jaundice 22.pptx
 

More from Dr.Sohel Memon

Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology)  V PharmDStudies of vaccine safety (Pharmacoepidemiology)  V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmDDr.Sohel Memon
 
Parkinsons disease V Pharm.D
Parkinsons disease V Pharm.DParkinsons disease V Pharm.D
Parkinsons disease V Pharm.DDr.Sohel Memon
 
Psoriasis and scabies by manaswi
Psoriasis and scabies by manaswiPsoriasis and scabies by manaswi
Psoriasis and scabies by manaswiDr.Sohel Memon
 
Tuberculosis presentation by Sohel Memon
Tuberculosis presentation by Sohel MemonTuberculosis presentation by Sohel Memon
Tuberculosis presentation by Sohel MemonDr.Sohel Memon
 

More from Dr.Sohel Memon (6)

Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology)  V PharmDStudies of vaccine safety (Pharmacoepidemiology)  V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
 
Parkinsons disease V Pharm.D
Parkinsons disease V Pharm.DParkinsons disease V Pharm.D
Parkinsons disease V Pharm.D
 
COPD by Vineela N.
COPD by Vineela N.COPD by Vineela N.
COPD by Vineela N.
 
Psoriasis and scabies by manaswi
Psoriasis and scabies by manaswiPsoriasis and scabies by manaswi
Psoriasis and scabies by manaswi
 
Eczema by Manaswi
Eczema by ManaswiEczema by Manaswi
Eczema by Manaswi
 
Tuberculosis presentation by Sohel Memon
Tuberculosis presentation by Sohel MemonTuberculosis presentation by Sohel Memon
Tuberculosis presentation by Sohel Memon
 

Recently uploaded

Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - Englishneillewis46
 
Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxPooja Bhuva
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentationcamerronhm
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17Celine George
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.christianmathematics
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Pooja Bhuva
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.pptRamjanShidvankar
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxannathomasp01
 
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxOn_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxPooja Bhuva
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Pooja Bhuva
 
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...Nguyen Thanh Tu Collection
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxPooja Bhuva
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Jisc
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfPoh-Sun Goh
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxRamakrishna Reddy Bijjam
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxAreebaZafar22
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxJisc
 

Recently uploaded (20)

Graduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - EnglishGraduate Outcomes Presentation Slides - English
Graduate Outcomes Presentation Slides - English
 
Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
 
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxOn_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
 
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Towards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptxTowards a code of practice for AI in AT.pptx
Towards a code of practice for AI in AT.pptx
 

Jaundice V PharmD by Vineela.N

  • 2. Contents of the topic  Definition  Classification  Signs and symptoms  Diagnosis  Pathophysiology  Prevention  Treatment
  • 3. Definition : Jaundice, as in the French jaune, refers to the yellow discoloration of the skin. Also known as Icterus Jaundice is a liver disease characterized by elevated levels of bilirubin in the blood termed as hyperbilirubinaemia. Normal range of serum bilirubin concentration is 0.31.3mg/dl Jaundice occurs when bilirubin levels exceeds 2mg/dl
  • 4.  Introduction to Bilirubin : Bilirubin is a orange-yellow pigment formed in the liver by the breakdown of hemoglobin and excreted in bile.  Two types of bilirubin : Conjugated and Unconjugated bilirubin  Sources of Bilirubin : • Catabolism of heme of hemoglobin (80-85%) • Non-hemoglobin heme containing pigments such as myoglobin, catalase and cytochromes
  • 5. Conjugated Bilirubin Unconjugated Bilirubin Water soluble Water Insoluble It reacts quickly to produce azobilirubin It reacts slowly to produce azobilirubin It produces azobilirubin only in the presence of dye It produces azobilirubin in the absence of dye Known by Direct bilirubin Known by Indirect bilirubin
  • 7.
  • 8. Types of Jaundice  Prehepatic Jaundice  Intrahepatic jaundice  Post hepatic Jaundice
  • 9.
  • 10. Type of Jaundice Pre-Hepatic Intra-hepatic Post-Hepatic Other Name Hemolytic jaundice Hepatocellular Jaundice Obstructive/ Regurgitation Jaundice Cause Increased hemolysis of erythrocytes Examples Malaria, sickle cell anemia, incompatible blood transfusion Dysfunction of liver Obstruction of bile due to damage to duct – prevents the parenchymal cells passage of bile into intestine Viral infection(hepatitis), poisons and toxins(chloroform, carbon tetrachloride, phosphorus), cirrhosis Gallstones, cancer of pancreas, gall bladder and bile duct
  • 11. Type of Jaundice Pre-Hepatic Intra-hepatic Post-Hepatic Biochemical characteristics serum unconjugated bilirubin serum conjugated and unconjugated bilirubin, SGPT and SGOT Serum conjugated bilirubin and ALP Clinical manifestations Dark brown color stools Nausea and anorexia Nausea; GI pain and clay colored feces Absent Absent Increased Increased Stercobilinogen Increased content Urobilinogen content Increased
  • 12.
  • 14. Common Drugs Associated With Hyperbilirubinemia HEPATOCELLULAR CAUSES • • • • • • • • • • • Acetominophen Alcohol Amiodarone Azulfidine Carbenicillin Clindamycin Colchicine Cyclophosphamide Diltiazem Ketoconazole Methyldopa • • • • • • • • • • Niacin Nifedipine NSAIDs Propylthiouracil Pyridium Pyrazinamide Quinidine Rifampicin Salicylates Verapamil
  • 15. Common Drugs Associated With Hyperbilirubinemia CHOLESTATIC CAUSES                     Amitriptyline Androgenic steroids (B) Atenolol Augmentin Azathioprine Bactrim (D) Benzodiazeprines Captopril Carbamazole Chlordiazepoxide (D)) Clofibrate Coumadin Cyclosporine Danazol (B) Dapsone Disopyramide Erythromycin Estrogens (B) Ethambutol Floxuridine                     5-Flucytosine Fluoroquinolones Griseofulvin Haloperidol (D) Labetolol Nicotinic acid NSAIDs Penicillins Phenobarbital Phenothiazines (D) Phenytoin Tamoxifen Tegretol Thiabendazole (D) Thiazides Thiouracil Tolbutamide (D) Tricyclics (D) Verapamil Zidovudine
  • 16. Etiopathogenesis 1. 2. 3. 4. 5. Increased bilirubin production Reduced bilirubin uptake by hepatic cells Disrupted intracellular conjugation Disrupted secretion of bilirubin into bile canaliculi Intra/extra-hepatic bile duct obstruction Lead to increases in free (unconj.) bilirubin Result in rise in conj. bilirubin levels
  • 17. 1. INCREASED BILIRUBIN PRODUCTION (unconj. Hyperbilirubinemia)  Hemolysis  Increased destruction of RBCs eg sickle cell anemia, thalassemia    Drastic increase in the amount of bilirubin produced Unconj. bilirubin levels rise due to liver’s inability to catch up to the increased rate of RBC destruction Prolonged hemolysis may lead to precipitation of bilirubin salts in the gall bladder and biliary network - result in formation of gallstones and conditions such as cholecystitis and biliary obstruction  Other   Degradation of Hb originating from areas of tissue infarctions and hematomas Ineffective erythropoiesis
  • 18. 2. DECREASED HEPATIC UPTAKE (unconj. Hyperbilirubinemia)  Several drugs have been reported to inhibit bilirubin uptake by the liver e.g. novobiocin, flavopiridol Hepatic cell Plasma Alb Bile B B + GST Alb B :GST B + UDPGA CB UGT1A1 sER MRP2
  • 19. 3) DISRUPTED INTRACELLULAR CONJUGATION (unconj. Hyperbilirubinemia) Neonatal jaundice occurs in 50% of newborns fetal bilirubin is eliminated by mother’s liver causes: hepatic mechanisms are not fully developed resulting in decreased ability to conjugate bilirubin rate of bilirubin production is increased due to shorter lifespan of RBCs Acquired disorders hepatitis, cirrhosis impaired liver function
  • 20.
  • 21. Crigler-Najjar Syndrome, Type I (CN-I) recessive allele; mutation-induced loss of conjugating ability in the critical enzyme glucuronosyltransferase CN-II greatly reduced but detectable glucuronosyltransferase activity due to mutation (predominantly recessive); enzymatic activity can be induced by drugs  Gilbert’s Syndrome glucuronosyl transferase activity reduced to 1030% of normal; also accompanied by defective bilirubin uptake mechanism
  • 22. 4) DISRUPTED SECRETION OF BILIRUBIN INTO BILE CANALICULI (conj. Hyperbilirubinemia)  Dubin–Johnson Syndrome  mild conj. hyperbilirubinemia, but can increase with concurrent illness, pregnancy, and use of oral contraceptives; otherwise asymptomatic    Inability of hepatocytes to secrete CB after it has formed Due to mutation in the MRP2 gene (autosomal recessive trait) Rotor Syndrome  Autosomal recessive condition characterized by increased total bilirubin levels due to a rise in CB  Caused by a defect in transport of bilirubin into bile
  • 23.
  • 24. 5) Intra/extra-hepatic bile duct obstruction  Intra-hepatic Obstruction of bile canaliculi, bile ductules or hepatic ducts  Extra-hepatic Obstruction of cystic duct or common bile duct Cholecystitis  Obstruction causes backup and reabsorption of CB which results in increased blood levels of CB
  • 25. Signs and Symptoms  Skin and sclerae - yellow  Stool - light colour, clay coloured  Dark urine  Pain in abdomen  Itching  Trouble with sleeping  Fatigue  Swelling  Ascites  Mental confusion  Coma  Bleeding
  • 26. Diagnosis  Medical history and examination  Urine test  Liver function and blood tests  Imaging tests  Liver biopsy
  • 27.  Medical history and physical examination Patient interview for - abdominal pain, itchy skin or weight loss malaria or hepatitis A change of colour in your urine and stools history of prolonged alcohol misuse Flu like symptoms Medications Occupation Physical examination : - Yellowish discoloration of eye and skin Swelling of legs, ankle and feet Hepatomegaly
  • 28.  Urine test : - to measure levels of a substance called urobilinogen - more than normal urobilinogen levels : Pre and Intra hepatic jaundice - Less than normal urobilinogen level : Post hepatic jaundice  Liver function and blood tests : Damage to liver releases liver enzymes like SGPT, SGOT and ALP and proteins, this indicates - Hepatitis - Alcoholic liver disease - cirrhosis
  • 29.  Imaging tests - CT Scan - MRI Scan - Ultrasound Scan - Endoscopic retrograde cholangiopancreatography (ERCP) Used to check for abnormalities inside the liver or bile duct systems.  Liver biopsy Used to diagnosis Cirrhosis and liver cancer.
  • 30.
  • 31. Jaundice treatment The treatment given to someone with jaundice will depend on what type they have, how serious it is and what caused it. It may include tackling an underlying condition such as malaria and bothersome symptoms, such as itching. For genetic conditions that don't get better, like sickle cell anaemia, a blood transfusion may be given to replenish red blood cells in the body. If the bile duct system is blocked, an operation may be needed to unblock it. During these procedures measures may be taken to help prevent further problems, such as removal of the gallbladder. If the liver is found to be seriously damaged, a transplant may be an option
  • 32. Treatment & Therapeutic Considerations PHOTOTHERAPY  Through absorption of the wavelengths at the blue end of the spectrum (blue, green and white light), bilirubin is converted into water-soluble photoisomers. This transformation enhances the molecule’s excretion into bile without conjugation.
  • 33. PHENOBARBITAL  This drug is not approved by FDA for use in neither adult nor pediatric hyperbilirubinemia patients, due to possibility of significant systemic side-effects.  Exact pathway is not known, but it is believed to act as an inducing agent on UDP-glucuronosyl transferase, thereby improving conjugation of bilirubin and its excretion. ALBUMIN  A 25% infusion can be used in treating hyperbilirubinemia (esp. due to hemolytic disease).  It is used in conjunction with exchange transfusion to bind bilirubin, enhancing its removal.
  • 34. CLOFIBRATE (ATROMID-S)  This drug has been shown to reduce bilirubin levels via an unknown mechanism.  Clofibrate is also associated with increased risk of developing cholelithiasis, cholecystitis, as well as functional liver abnormalities, which can worsen hyperbilirubinemia. PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY  Allows extraction of stones and thus removal of the source of obstruction when present.
  • 35. Prevention of Jaundice : • Limit alcohol intake to not more than two drinks a day for men or one drink a day for women. • Avoid exposure to industrial chemicals. • Do not use illegal drugs. • Do not share needles or nasal snorting equipment. • Vaccination : Hepatitis A and Hepatitis B • Maintain healthy body weight.